Related Experiment Video

Updated: Aug 20, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

Simvastatin Therapy Increased miR-150-5p
Expression in the Patients with Type 2 Diabetes and COVID-19

Mandana AmeliMojarad1, Melika AmeliMojarad2, Alireza Pourmadian2

  • 1Department of Biotechnology, Tehran University of Medical Science, Tehran, Iran, Mandanalee13@gmail.com.

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|November 25, 2022
PubMed

Insights

Simvastatin treatment increased miR-150-5p levels in patients with Type 2 Diabetes Mellitus (T2DM) and COVID-19, improving immune response and lipid profiles. This suggests simvastatin as a potential adjunct therapy for T2DM patients with COVID-19.

Area of Science:

  • * Virology and Immunology
  • * Endocrinology and Metabolism
  • * Pharmacology

Background:

  • * Coronavirus disease 2019 (COVID-19) presents significant challenges for individuals with comorbidities like diabetes, often leading to more severe disease due to blood glucose fluctuations.
  • * Statins, primarily known for lipid-lowering effects, also possess anti-inflammatory and immunomodulatory properties that can influence microRNA (miRNA) expression.

Purpose of the Study:

  • * To investigate the impact of simvastatin on miR-150-5p expression in patients with Type 2 Diabetes Mellitus (T2DM) and COVID-19.
  • * To assess the association of miR-150-5p modulation with immune and lipid profiles in these patients.
  • * To evaluate simvastatin's potential as an adjunct therapy for T2DM patients with COVID-19.

Main Methods:

  • * Real-time PCR was used to measure miR-150-5p expression in 30 T2DM patients with COVID-19 before and after a 2-month simvastatin treatment, compared to COVID-19 patients without diabetes.
  • * Bioinformatics analysis was employed to identify target genes of miR-150-5p.
  • * Gene Ontology (GO) enrichment analysis was utilized to determine the functions of these target genes.

Main Results:

  • * Simvastatin treatment significantly increased miR-150-5p expression in T2DM patients with COVID-19.
  • * This increase in miR-150-5p led to the downregulation of its target genes involved in immune stimulation.
  • * Simvastatin also resulted in a decrease in lipid profiles, including LDL-C, total cholesterol, and ApoB, particularly in the T2DM and COVID-19 cohort.

Conclusions:

  • * Simvastatin demonstrates anti-inflammatory effects by modulating miRNA expression, specifically increasing miR-150-5p.
  • * The drug effectively improves lipid profiles and influences immune response pathways in T2DM patients with COVID-19.
  • * Simvastatin shows promise as an adjunctive therapy for managing T2DM patients concurrently infected with COVID-19, warranting further in vivo investigation for miRNA-targeted treatments.
Abstract

Keywords:
miR-150-5p; COVID-19; T2DM; Statin; Simvastatin

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

256

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
751
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
328